In the past few years, we witnessed rapid progress in the treatment of hepatobiliary tumors, owing to the crucial role of tyrosine kinase inhibitors and immune checkpoint inhibitors in immunotherapy. Immunotherapy manipulates the immune system to recognize and attack tumor cells and has displayed promising clinical effects in the treatment of advanced hepatobiliary tumors. Nevertheless, low objective response rate and therapy resistance still represent major challenges for immunotherapy. Primary immunotherapy resistance is ubiquitous in more than half of patients due to immune escape in hepatobiliary tumors. Uncovering the mechanisms of immunotherapy resistance and screening out the targeted patients for immunotherapy is important for the precise treatment of hepatobiliary tumors.
Application of preoperative treatments may lead to tumor downstaging in some advanced-stage patients and consequently provide them with opportunities for curative therapy, representing a breakthrough treatment strategy for advanced hepatobiliary tumors. However, conversion studies on patient selection, choice of treatment method, and postoperative management are still lacking. The five-year recurrence rate after curative treatments is up to 70% in hepatobiliary tumors. The value of postoperative adjuvant therapy in the prevention of tumor recurrence is still in debate. In addition, the immunomodulatory effects of tyrosine kinase inhibitors on the tumor microenvironment should also be evaluated.
In this Research Topic, we mainly focus on the critical role of tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of hepatobiliary tumors and investigate the mechanisms of immunotherapy resistance. In addition, we also aim to elucidate the immunomodulatory effects of tyrosine kinase inhibitors on immunotherapy and to identify the appropriate patients which may provide promising strategies in target therapy and immunotherapy of hepatobiliary tumors.
This Research Topic welcomes submissions of Review, Mini-Review, Clinical Trials, and Original Research articles covering, but not limited to, the following subtopics:
1) The synergistic effect of tyrosine kinase inhibitors on immunotherapy and adoptive cell therapy for hepatobiliary tumors.
2) The detailed mechanisms of immunotherapy resistance in advanced hepatobiliary tumors.
3) The mechanisms of immunotherapy inhibiting tumor proliferation and metastasis.
4) Immunomodulatory effects of tyrosine kinase inhibitors on immunotherapy in vivo and in vitro.
5) The role of tumor microenvironment in tumor progression and immunotherapeutic efficacy for hepatobiliary tumors.
6) Clinical studies of local treatments on combined therapy of tyrosine kinase inhibitors and immunotherapy for advanced hepatobiliary tumors.
7) Clinical studies of tyrosine kinase inhibitors and immune checkpoint inhibitors on postoperative adjuvant therapy for hepatobiliary tumors.
8) Conversion therapy in hepatobiliary tumors.
*Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation in vitro or in vivo are out of scope for this section and will not be accepted as part of this Research Topic.
In the past few years, we witnessed rapid progress in the treatment of hepatobiliary tumors, owing to the crucial role of tyrosine kinase inhibitors and immune checkpoint inhibitors in immunotherapy. Immunotherapy manipulates the immune system to recognize and attack tumor cells and has displayed promising clinical effects in the treatment of advanced hepatobiliary tumors. Nevertheless, low objective response rate and therapy resistance still represent major challenges for immunotherapy. Primary immunotherapy resistance is ubiquitous in more than half of patients due to immune escape in hepatobiliary tumors. Uncovering the mechanisms of immunotherapy resistance and screening out the targeted patients for immunotherapy is important for the precise treatment of hepatobiliary tumors.
Application of preoperative treatments may lead to tumor downstaging in some advanced-stage patients and consequently provide them with opportunities for curative therapy, representing a breakthrough treatment strategy for advanced hepatobiliary tumors. However, conversion studies on patient selection, choice of treatment method, and postoperative management are still lacking. The five-year recurrence rate after curative treatments is up to 70% in hepatobiliary tumors. The value of postoperative adjuvant therapy in the prevention of tumor recurrence is still in debate. In addition, the immunomodulatory effects of tyrosine kinase inhibitors on the tumor microenvironment should also be evaluated.
In this Research Topic, we mainly focus on the critical role of tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of hepatobiliary tumors and investigate the mechanisms of immunotherapy resistance. In addition, we also aim to elucidate the immunomodulatory effects of tyrosine kinase inhibitors on immunotherapy and to identify the appropriate patients which may provide promising strategies in target therapy and immunotherapy of hepatobiliary tumors.
This Research Topic welcomes submissions of Review, Mini-Review, Clinical Trials, and Original Research articles covering, but not limited to, the following subtopics:
1) The synergistic effect of tyrosine kinase inhibitors on immunotherapy and adoptive cell therapy for hepatobiliary tumors.
2) The detailed mechanisms of immunotherapy resistance in advanced hepatobiliary tumors.
3) The mechanisms of immunotherapy inhibiting tumor proliferation and metastasis.
4) Immunomodulatory effects of tyrosine kinase inhibitors on immunotherapy in vivo and in vitro.
5) The role of tumor microenvironment in tumor progression and immunotherapeutic efficacy for hepatobiliary tumors.
6) Clinical studies of local treatments on combined therapy of tyrosine kinase inhibitors and immunotherapy for advanced hepatobiliary tumors.
7) Clinical studies of tyrosine kinase inhibitors and immune checkpoint inhibitors on postoperative adjuvant therapy for hepatobiliary tumors.
8) Conversion therapy in hepatobiliary tumors.
*Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation in vitro or in vivo are out of scope for this section and will not be accepted as part of this Research Topic.
